FGFR3 (K650E)
Sign in to save this workspaceFGFR3 · Variant type: point · HGVS: p.K650E
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Futibatinib | 100.0% | 0.0% | 98.48 |
| 2 | Alpelisib | 99.9% | 0.1% | 97.22 |
| 3 | Erdafitinib | 99.7% | 0.3% | 95.71 |
| 4 | Infigratinib | 99.6% | 0.4% | 98.24 |
| 5 | Pemigatinib | 99.2% | 0.8% | 98.23 |
| 6 | Selpercatinib | 99.0% | 1.0% | 96.72 |
| 7 | Brigatinib | 98.8% | 1.2% | 82.96 |
| 8 | Tenalisib | 98.6% | 1.4% | 97.98 |
| 9 | Deucravacitinib | 98.0% | 1.9% | 98.99 |
| 10 | Nintedanib | 97.3% | 2.8% | 90.23 |
| 11 | Pralsetinib | 97.0% | 3.0% | 93.43 |
| 12 | Ponatinib | 96.9% | 3.1% | 78.23 |
| 13 | Vandetanib | 91.0% | 9.0% | 95.74 |
| 14 | Axitinib | 89.8% | 10.2% | 93.23 |
| 15 | Lenvatinib | 83.4% | 16.6% | 97.74 |
| 16 | Pazopanib | 81.2% | 18.8% | 97.49 |
| 17 | Fedratinib | 80.5% | 19.5% | 96.21 |
| 18 | Tivozanib | 79.8% | 20.1% | 92.42 |
| 19 | Entrectinib | 79.2% | 20.8% | 93.69 |
| 20 | Sunitinib | 77.9% | 22.1% | 91.73 |
| 21 | Tepotinib | 75.9% | 24.1% | 99.75 |
| 22 | Canertinib | 75.3% | 24.7% | 96.49 |
| 23 | Ripretinib | 74.5% | 25.5% | 92.95 |
| 24 | Regorafenib | 74.2% | 25.8% | 95.99 |
| 25 | Pexidartinib | 69.7% | 30.3% | 99.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Futibatinib | 100.0% | 99.0% | +1.0% |
| Alpelisib | 99.9% | 98.6% | +1.3% |
| Erdafitinib | 99.7% | 99.1% | +0.6% |
| Infigratinib | 99.6% | 98.6% | +1.0% |
| Pemigatinib | 99.2% | 99.4% | -0.1% |
| Selpercatinib | 99.0% | 86.6% | +12.4% |
| Brigatinib | 98.8% | 74.6% | +24.2% |
| Tenalisib | 98.6% | 98.0% | +0.6% |
| Deucravacitinib | 98.0% | 93.3% | +4.8% |
| Nintedanib | 97.3% | 91.0% | +6.3% |
| Pralsetinib | 97.0% | 90.6% | +6.4% |
| Ponatinib | 96.9% | 96.7% | +0.2% |
| Vandetanib | 91.0% | — | — |
| Axitinib | 89.8% | 93.1% | -3.3% |
| Lenvatinib | 83.4% | 79.9% | +3.5% |
| Pazopanib | 81.2% | 78.7% | +2.5% |
| Fedratinib | 80.5% | 67.1% | +13.4% |
| Tivozanib | 79.8% | — | — |
| Entrectinib | 79.2% | 73.3% | +5.9% |
| Sunitinib | 77.9% | 66.2% | +11.6% |
| Tepotinib | 75.9% | — | — |
| Canertinib | 75.3% | — | — |
| Ripretinib | 74.5% | — | — |
| Regorafenib | 74.2% | — | — |
| Pexidartinib | 69.7% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Myeloma | Blood/Lymphatic System | ref |
| Bladder Cancer | Bladder | ref |
| other_skin | Skin | ref |
| carcinoma_urinary_tract | Biliary Tract | ref |
| glioma_central_nervous_system | Brain/CNS | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| germ_cell_tumour_testis | Genitourinary system | ref |
| carcinoma_breast | Breast | ref |
| carcinoma_skin | Skin | ref |
| BLCA-CN | Bladder | ref |
| BLCA-US | Bladder | ref |
| MM | Blood/Lymphatic System | ref |
| BLCA | Bladder | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 32.7ms